YAP1 and breast cancer: Among the screened 374 small molecule compounds, Abemaciclib, a highly selective CDK4/6 inhibitor approved by FDA for breast cancer treatment [16], exhibited the strongest inhibitory effect, reducing YAP1 activity by more than 70% (Fig. 1B).